argenex (NASDAQ:ARGX) Price Target Raised to $1,135.00 at Guggenheim

argenex (NASDAQ:ARGX) had its price target hoisted by Guggenheim from $1,120.00 to $1,135.00 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently commented on ARGX. Citizens Jmp upped their price objective on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Oppenheimer cut their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Finally, Royal Bank Of Canada cut their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,017.78.

argenex Trading Down 0.7%

NASDAQ:ARGX opened at $782.17 on Friday. The firm has a market cap of $48.64 billion, a price-to-earnings ratio of 34.83, a price-to-earnings-growth ratio of 1.29 and a beta of 0.46. The company’s 50-day moving average is $755.88 and its two-hundred day moving average is $817.54. argenex has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, May 7th. The company reported $5.52 EPS for the quarter, missing analysts’ consensus estimates of $5.75 by ($0.23). argenex had a net margin of 31.31% and a return on equity of 33.28%. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.44 billion. On average, equities research analysts forecast that argenex will post 24.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenex

Several institutional investors and hedge funds have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its stake in shares of argenex by 17.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,796 shares of the company’s stock valued at $2,772,000 after buying an additional 570 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of argenex by 5.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 38,794 shares of the company’s stock valued at $28,327,000 after buying an additional 1,977 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of argenex by 4.3% during the 1st quarter. Parallel Advisors LLC now owns 553 shares of the company’s stock valued at $404,000 after buying an additional 23 shares during the last quarter. Boston Common Asset Management LLC purchased a new position in shares of argenex during the 1st quarter valued at approximately $2,741,000. Finally, AlphaCentric Advisors LLC boosted its stake in shares of argenex by 25.9% during the 1st quarter. AlphaCentric Advisors LLC now owns 1,794 shares of the company’s stock valued at $1,310,000 after buying an additional 369 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Guggenheim raised its price target on argenx to $1,135 and kept a buy rating, implying substantial upside from current levels. Guggenheim Raises ARGX Price Target
• Positive Sentiment: Wells Fargo also increased its price target to $1,260 and reiterated an overweight rating, signaling continued confidence in argenx’s long-term growth prospects. Wells Fargo Raises ARGX Price Target
• Neutral Sentiment: argenx reported Q1 2026 results and a business update, with investors parsing the details of the quarter and management’s outlook. argenx Q1 2026 Financial Results and Business Update
• Negative Sentiment: The company posted earnings of $5.52 per share, below the $5.79 consensus estimate, and revenue of $1.31 billion also missed expectations, which is likely weighing on the stock. Argenx Tops Earnings Expectations Despite Slight Revenue Shortfall

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.